Part of the Contemporary Cardiology book series (CONCARD)


Stable angina is defined as short duration chest and/or arm discomfort that shows no change in the past 60 days in frequency, duration, or precipitating causes. Most often pain duration is less than 10 minutes, and rarely up to 15 minutes; the mild-to-moderate discomfort is relieved within 1 to 10 minutes by cessation of the precipitating activity or use of sublingual nitroglycerin.


Coronary Artery Bypass Graft Left Anterior Descend Calcium Antagonist Unstable Angina Stable Angina 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Åblad B, Bjurö T, Björkman JA, Edström T, Olsson G. Role of central nervous beta-adrenoceptors in the prevention of ventricular fibrillation through augmentation of cardiac vagal tone. J Am Coll Cardiol 1991;17(suppl):165.Google Scholar
  2. 2.
    Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342–1349.PubMedCrossRefGoogle Scholar
  3. 3.
    Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835–842.PubMedCrossRefGoogle Scholar
  4. 4.
    Antooniucci D, Rodriguez A, Hempel A, et al. a randomized trials comparing primary infarct artery stenting with or without abciximab. J Am Coll Cardiol 2003;42:1879–1885.CrossRefGoogle Scholar
  5. 5.
    Barbato E, Piscione F, Bartunek J, et al. Role of β2 adrenergic receptors in human aterosclerotic coronary arteries. Circulation 2005;111:288–294.PubMedCrossRefGoogle Scholar
  6. 6.
    Berger P. Ranolazine and other antianginal therapies in the era of the drug-eluting stent. JAMA 2004;291(3):365–367.PubMedCrossRefGoogle Scholar
  7. 7.
    Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Unstable Angina and Non-ST Segment Elevation Myocardial Infarction). J Am Coll Cardiol 2000;36:970–1056.PubMedCrossRefGoogle Scholar
  8. 8.
    Budoff MJ, Achenbach S, Duerinck A. clinical utility of computed tomography and magnetic resonance techniques for noninvasive coronary angiography. J Am Coll Cardiol 2003;42:1867–1878.PubMedCrossRefGoogle Scholar
  9. 9.
    CABRI Trial Participants. First-yearresults of C ABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). Lancet 1995;346:1179.CrossRefGoogle Scholar
  10. 10.
    Cameron AA, Green GE, Brogno DA, et al. Internal thoracic artery grafts: 20-year clinical follow-up. J Am Coll Cardiol 1995;25:188.PubMedCrossRefGoogle Scholar
  11. 11.
    Cameron AAC, David KB, Rogers WJ, et al. Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). J Am Coll Cardiol 1995;26:895.PubMedCrossRefGoogle Scholar
  12. 12.
    Cameron A, Davis KB, Green G, et al. Coronary bypass surgery with internal-thoracic-artery grafts-effects on survival over 15 year period. N Engl J Med 1996;334:216.PubMedCrossRefGoogle Scholar
  13. 13.
    Cannon CP, Braunwald E, McCabe CH. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [PROVE IT-TIMI 22 trial]. N Engl J Med 2004;350:1495–1504.PubMedCrossRefGoogle Scholar
  14. 14.
    Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q-wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. J Am Coll Cardiol 1997;30:133–140.PubMedCrossRefGoogle Scholar
  15. 15.
    Cannon CP, Turpie AG. Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy. Circulation 2003;107:2640–2645.PubMedCrossRefGoogle Scholar
  16. 16.
    CAPRICORN: the CAPRICORN investigators: effect of carvedilol on outcome after myocardial infarction in patients and with left ventricular dysfunction: Lancet 2001;357:1385.CrossRefGoogle Scholar
  17. 17.
    The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13.Google Scholar
  18. 18.
    Chaitman BR, Pepine CJ, Parker JO, et al., Combination Assessment of Ranolazine In Stable Angina (CARISA). Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309–316.PubMedCrossRefGoogle Scholar
  19. 19.
    Cheng J-J, Wung BS, Chao Y J, et al. cyclic strain enhances adhesion of monocytes to endothelial cells by increasing intercellular adhesion molecule-1 expression. Hypertension 1996;28:386–391.PubMedGoogle Scholar
  20. 20.
    Colombo A, Stankovic G, Moses JW. Selection of coronary stents. J Am Coll Cardiol 2002;40:1021–1033.PubMedCrossRefGoogle Scholar
  21. 21.
    Cominacini L, Fratta Pasini A, Garbin U, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003;42:1838–1844.PubMedCrossRefGoogle Scholar
  22. 22.
    COPERNICUS: Packer M, Coast JS, Fowler MB, et al. for the carvedilol prospective in randomized cumulative survival study group: effect of carvedilol on survival in severe chronic heart failure. New Engl J Med 2001;344:1651.PubMedCrossRefGoogle Scholar
  23. 23.
    Cruickshank JM. Beta-blockers continue to surprise us Eur Heart J 2000;21:355.CrossRefGoogle Scholar
  24. 24.
    Dargie HJ, Ford I, Fox K. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996;17:104–112PubMedGoogle Scholar
  25. 25.
    Fattori R, Piva T. Drug-eluting stents in vascular intervention Lancet 361:247–49, 2003PubMedCrossRefGoogle Scholar
  26. 26.
    Fleming SM, O’Byrne L, Finn J, et al. False-positive cardiac troponin I in a routine clinical population. Am J Cardiol 2002;89:1212–1215.PubMedCrossRefGoogle Scholar
  27. 27.
    Goldman S, Zadina K, Moritz T, et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery. J Am Coll Cardiol 2004;44:2149–2156.PubMedCrossRefGoogle Scholar
  28. 28.
    Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P) H oxidase; role in cardiovascular biology and disease. Circ Res 2000;86:494–501.PubMedGoogle Scholar
  29. 29.
    Goy J-J, Stauffer J-C, Siegenthaler M, et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology, The TAXi trial. J Am Coll Cardiol 2004;45:308–311.CrossRefGoogle Scholar
  30. 30.
    Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623–1629.PubMedCrossRefGoogle Scholar
  31. 31.
    Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med 1995;333:1267.PubMedCrossRefGoogle Scholar
  32. 32.
    The Joint European Society of Cardiology/ American College of Cardiology committee. Myocardial infarction redefined: a consensus document of the joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502–1513.CrossRefGoogle Scholar
  33. 33.
    Kastrati A, Mehilli J, Schuhlen H, et al. Intracoronary stenting and antithrombotic regimen-rapid early action for coronary treatment study investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232–238.PubMedCrossRefGoogle Scholar
  34. 34.
    Khan M Gabriel. β-blockers the cornerstone of cardiac drug therapy. In Cardiac Drug Therapy. 6th ed. Philadelphia: WB Saunders/Elsevier, 2003.Google Scholar
  35. 35.
    King SB, Lembo NJ, Weintraub WS, et al. For the Emory Angioplasty versus Surgery Trial: A randomized trial comparing coronary angioplasty with coronary bypass surgery. N Eng J Med 1994;331:1044.CrossRefGoogle Scholar
  36. 36.
    Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Sumamry: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging. Circulation 2003;108:1404–1418.PubMedCrossRefGoogle Scholar
  37. 37.
    Kramer CM. The comprehensive approach to ischemic heart disease by cardiovascular magnetic resonance imaging. J Am Coll Cardiol 2004;44:2182–2184.PubMedCrossRefGoogle Scholar
  38. 38.
    Lange RA, Hillis LD. Antiplatelet therapy for ischemic heart disease. N Engl J Med 2004;350:277–280.PubMedCrossRefGoogle Scholar
  39. 39.
    Loscalzo J, Bonow RO, Jacobs AK. Coronary calcium screening and the American Heart Association news embargo. Circulation 2004;110:3504–3505.PubMedCrossRefGoogle Scholar
  40. 40.
    Macaya C, Serruys PW, Ruygrok P, et al. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. J Am Coll Cardiol 1996;27:255.PubMedCrossRefGoogle Scholar
  41. 41.
    Maehara A, Mintz GS, Bui AB, et al. The morphologic and angiographic features of coronary plaque rupture detected by intravascular ultrasound. J Am Coll Cardiol 2002;40:904–910.PubMedCrossRefGoogle Scholar
  42. 42.
    Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive versus conservative strategy for the treatment of unstable angina and non-ST elevation myocardial infarction. JAMA 2002;288:1851–1858.PubMedCrossRefGoogle Scholar
  43. 43.
    Mallik S, Krumholz HM, Lin ZQ, et al. Patients with depressive symptoms have lower health status benefits after coronary artery bypass surgery. Circulation 2005;111:271–277.PubMedCrossRefGoogle Scholar
  44. 44.
    MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomized trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001–2007.CrossRefGoogle Scholar
  45. 45.
    Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol 2004;44:2099–2110.PubMedCrossRefGoogle Scholar
  46. 46.
    Morice MC, Serruys PW, Sousa JE, et al. for the RAVEL study group. A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773–1780.PubMedCrossRefGoogle Scholar
  47. 47.
    Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponin I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001;286:2405–2412.PubMedCrossRefGoogle Scholar
  48. 48.
    The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1989:319:385.Google Scholar
  49. 49.
    Muni NI, Gross TP. Problems with drug-eluting coronary stents—the FDA perspective. N Engl J Med 2004;351:1593–1595.PubMedCrossRefGoogle Scholar
  50. 50.
    Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995;95:187–194PubMedCrossRefGoogle Scholar
  51. 51.
    Nemoto S, Hamawaki M, DeFreitas G et al. Differential effects of the angiotensin-converting enzyme inhibitor lisinopril versus the β-adrenergic receptor blocker atenolol on hemodynamics and left ventricular contractile function in experimental mitral regurgitation. J Am Coll Cardiol 2002;40:149–154.PubMedCrossRefGoogle Scholar
  52. 52.
    Okada M, Matsumori A, Ono K et al. cyclic stretch upregulates production of interleukin-8 and monocyte chemotactic and activating factor/ monocyte chemoattractant protein-1 in human endothelial cells. Arterioscler Thromb Vasc Biol 1998;18:894–901.PubMedGoogle Scholar
  53. 53.
    Park SJ, Kim YH, Lee BK, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis. J Am Coll Cardiol 2005;45:351–356.PubMedCrossRefGoogle Scholar
  54. 54.
    Park S-J, Shim WH, Ho DS, et al. A placlitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537–1545.PubMedCrossRefGoogle Scholar
  55. 55.
    Parker JD. Therapy with nitrates: increasing evidence of vascular toxicity. J Am Coll Cardiol 2003;42:1835–1837.PubMedCrossRefGoogle Scholar
  56. 56.
    Peters RW, Muller JE, Goldstein S, et al. For the BHAT Study Group. Propranolol and the morning increase in the frequency of sudden cardiac deaths (BHAT Study). Am J Cardiol 1989;63:1518.PubMedCrossRefGoogle Scholar
  57. 57.
    Portegies MCM, Sijbring P, Gobel EJAM, et al. Efficacy of metoprolol and diltizem in treating silent myocardial ischemia. Am J Cardiol 1994;74:1095.PubMedCrossRefGoogle Scholar
  58. 58.
    Prakash C, Deedwania PC, Carbajal EV, et al. Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia. J Am Coll Cardiol 1991;17:963.CrossRefGoogle Scholar
  59. 59.
    RITA Trial Participants. Coronary angioplasty versus coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet 1993;341:573.CrossRefGoogle Scholar
  60. 60.
    Sakamoto H, Aikawa M, Hill CC. Biomechanical strain induces class A scavenger receptor expression in human monocyte/macrophages and THP-1 cells. Circulation 2001;104:109–114.PubMedCrossRefGoogle Scholar
  61. 61.
    Scirica BM, Cannon CP, McCabe CH, et al., Thrombolysis in Myocardial Ischemia III Registry Investigators. Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. Am J Cardiol 2002;90:821–826.PubMedCrossRefGoogle Scholar
  62. 62.
    Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon expandable-stent implantation with balloon angioplsty in patients with coronary artery disease. N Engl J Med 1994;331:489.PubMedCrossRefGoogle Scholar
  63. 63.
    Serruys PW, Ormiston JA, Sianos G, et al. Actinomycin-eluting stent for coronary revascularization. A randomized feasibility and safety study: The ACTION trial. J Am Coll Cardiol 2004;44:1363–1367.PubMedGoogle Scholar
  64. 64.
    Sharma GVRK, Deupree RH, Luchi RJ, et al. Indentification of unstable angina patients who have favorable outcome with medical or surgical therapy (eight-year follow-up of the veterans administration cooperative study. Am J Cardiol 1994;74:454.PubMedCrossRefGoogle Scholar
  65. 65.
    Stone GW, Ellis SG, Cox DA, et al., TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221–231.PubMedCrossRefGoogle Scholar
  66. 66.
    Taylor WR. Hypertensive vascular disease and inflammation: mechanical and humoral mechanisms. Current Hypertens Rep 1999;1:96–101.CrossRefGoogle Scholar
  67. 67.
    Topol EJ. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 2003;42:1886–1889.PubMedCrossRefGoogle Scholar
  68. 68.
    Théroux P, Ouimet H, McCans J. Aspirin, heparin, or both to treat unstable angina. N Engl J Med 1988:319:1105.PubMedCrossRefGoogle Scholar
  69. 69.
    Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 2002;105:393–343.CrossRefGoogle Scholar
  70. 70.
    Versaci F, Gaspardone A, Tomai F. et al. immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol. 2002;40:1935–1942.PubMedCrossRefGoogle Scholar
  71. 71.
    von Arnim T. Medical treatment of reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol 1995;25:231.CrossRefGoogle Scholar
  72. 72.
    Weintraub WS, Mauldin PD, Becker E, et al. A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease: results from the Emory Angioplasty Versus Surgery Trial (EAST). Circulation 1995;92:2831.PubMedGoogle Scholar
  73. 73.
    Wong SC, Bairn DS, Schatz RA, et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the Multicenter U.S. Palmaz-Schatz Stent Experience. J Am Coll Cardiol 1995;26:704.PubMedCrossRefGoogle Scholar
  74. 74.
    Wright SA, Sawyer DB, Sacks DB, et al. Elevation of troponin I levels in patients without evidence of myocardial injury. JAMA 1997;278:2144.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Personalised recommendations